Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

N. Tsavaris,Nikolaos Ziras,C. Kosmas,T Giannakakis,Panayiotis Gouveris,M. Vadiaka,Antonios Dimitrakopoulos,D. Karadima,Sofia Rokana,Efstathios Papalambros,G. Papastratis,Helias Margaris,Heracles Tsipras,A. Polyzos

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

2003

N. Tsavaris
Nikolaos Ziras
C. Kosmas
T Giannakakis
Panayiotis Gouveris
M. Vadiaka
Antonios Dimitrakopoulos
D. Karadima
Sofia Rokana
Efstathios Papalambros
G. Papastratis
Helias Margaris
Heracles Tsipras
A. Polyzos

Purpose To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy.

Keywords:

Fluorouracil
Thymidylate synthase
Oncology
Pharmacology
Cancer
Carcinoma
Colorectal cancer
Irinotecan
Chemotherapy
Antimetabolite
Internal medicine
Surgery
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations